Short Interest in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Increases By 32.4%

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 200,000 shares, a growth of 32.4% from the August 15th total of 151,100 shares. Based on an average daily volume of 72,500 shares, the short-interest ratio is presently 2.8 days. Currently, 1.2% of the company’s shares are sold short.

Analysts Set New Price Targets

CYTH has been the topic of several analyst reports. Maxim Group reaffirmed a “hold” rating on shares of Cyclo Therapeutics in a research report on Tuesday, August 27th. HC Wainwright restated a “neutral” rating and set a $0.95 price target (down previously from $3.00) on shares of Cyclo Therapeutics in a report on Friday, August 23rd. Finally, Ascendiant Capital Markets lowered their price objective on Cyclo Therapeutics from $2.60 to $0.95 and set a “buy” rating for the company in a research report on Monday, August 26th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cyclo Therapeutics stock. Founders Fund VI Management LLC acquired a new stake in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 110,023 shares of the company’s stock, valued at approximately $175,000. Cyclo Therapeutics comprises 1.4% of Founders Fund VI Management LLC’s portfolio, making the stock its 2nd largest holding. Founders Fund VI Management LLC owned approximately 0.48% of Cyclo Therapeutics as of its most recent SEC filing. 68.55% of the stock is owned by institutional investors.

Cyclo Therapeutics Price Performance

Shares of CYTH stock remained flat at $0.64 during mid-day trading on Monday. The company’s stock had a trading volume of 20,663 shares, compared to its average volume of 78,459. The firm’s 50-day moving average price is $1.03 and its two-hundred day moving average price is $1.25. Cyclo Therapeutics has a 12 month low of $0.59 and a 12 month high of $2.12. The company has a market capitalization of $18.37 million, a PE ratio of -0.64 and a beta of -0.38.

Cyclo Therapeutics (NASDAQ:CYTH) last released its quarterly earnings results on Thursday, August 15th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.07). The firm had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.40 million. Cyclo Therapeutics had a negative return on equity of 2,741.89% and a negative net margin of 1,830.27%. As a group, analysts anticipate that Cyclo Therapeutics will post -0.66 earnings per share for the current year.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.